China's investigator-initiated trials, once praised for their speediness, have been drawn into scrutiny for a lack of ...

Almost three years into his tenure as Lundbeck’s CEO, Charl van Zyl is confident the company can prove its mettle as a ...

Earnings calls are a chance to catch up with the latest developments across Big Pharma and beyond, and last quarter was no ...

Eight months after more than doubling down on its construction of a $2 billion drug manufacturing facility in Holly Springs, ...

Less than a year after the FDA turned down the resubmitted application for the company’s leukemia prospect Dasynoc, Xspray ...

For patients living with Type 2 diabetes in the United Kingdom, a more convenient treatment option may be on the horizon ...

Just eight months after it introduced its oral version of semaglutide for obesity, also known as the Wegovy pill, Novo ...

If at first you don’t succeed in gene therapy, then try, try again. | If at first you don’t succeed in gene therapy, then try ...

Aurinia Pharmaceuticals has struck a patent infringement settlement with Teva Pharmaceuticals, which should help stave off ...

B. Braun Medical—a maker of IV solutions for hospitals, among other products—has initiated a recall in the United States and ...

After more than 10 years in development, Regeneron secured a landmark approval for its monoclonal antibody garetosmab, now ...

In their attempts to challenge the Medicare drug price negotiation program, introduced by former President Joe Biden under ...